lipofectin (dotma plus dope Search Results


90
Thermo Fisher lipofectin (dotma:dope
Lipofectin (Dotma:Dope, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lipofectin (dotma:dope/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
lipofectin (dotma:dope - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

86
Thermo Fisher lipofectin
Lipofectin, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lipofectin/product/Thermo Fisher
Average 86 stars, based on 1 article reviews
lipofectin - by Bioz Stars, 2026-04
86/100 stars
  Buy from Supplier

90
Thermo Fisher lipofectin® (dotma/dope
Lipofectin® (Dotma/Dope, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lipofectin® (dotma/dope/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
lipofectin® (dotma/dope - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Thermo Fisher lipofectin (dotma/dope weight ratio 1:1
Lipofectin (Dotma/Dope Weight Ratio 1:1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lipofectin (dotma/dope weight ratio 1:1/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
lipofectin (dotma/dope weight ratio 1:1 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Thermo Fisher lipofectin® (dotma:dope
Lipofectin® (Dotma:Dope, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lipofectin® (dotma:dope/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
lipofectin® (dotma:dope - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Thermo Fisher dotma (lipofectin
Inhibition of HIV-1 infectivity by a MAPK antisense oligonucleotide (AS) or scrambled control oligonucleotide (SC). (A) Depletion of p44/42 MAPK expression by AS. HeLa cells were treated with AS or SC at the indicated concentrations. HeLa cells were grown to 80% confluence in Dulbecco’s minimal essential medium (DMEM) containing 10% FCS in 35-mm-diameter six-well plates, and washed twice with serum-free DMEM. Appropriate concentrations of oligonucleotides in 125 μl of serum-free DMEM were preincubated at room temperature for 15 min with 125 μl of serum-free DMEM containing 40 μg of <t>DOTMA</t> <t>(Lipofectin)</t> (Gibco-BRL) per ml. This solution was then mixed with an additional 250 μl of serum-free DMEM. Cells were incubated with the mixture for 6 h at 37°C in the presence of 5% CO2. Subsequently, the medium containing DOTMA was removed and the incubation was continued for 48 h in fresh medium containing 10% FCS. After 48 h incubation, MAPK expression was determined by immunoblotting of equivalent amounts of total protein with anti-MAPK (anti-ERK1 [p44] and anti-ERK2 [p42]). (B) HeLa cells were transfected with 3 μg of pHXB2 containing HIV-1 proviral DNA following depletion of MAPK by treatment with MAPK antisense oligonucleotide as described for panel A. Virus production was determined by quantitation of RT activity in the supernatants of the transfected HeLa cell cultures at 48 h after transfection. Virus infectivity was determined by infection of CEM cells and quantitation of RT activity in the supernatants of the newly infected cells on day 7 after infection. (C) Treatment with AS does not inhibit expression of an HIV-1 LTR CAT reporter plasmid transactivated by coexpression of HIV-1 Tat. HeLa cells were treated with the oligonucleotides at 0.2 μM and cotransfected with 0.5 μg of pUIIIRCAT and 0 or 0.5 μg of the HIV-1 Tat expressor plasmid pSVLtat by the same method as described for panels A and B. Shown is CAT activity in the transfected cell lysate at 48 h posttransfection, as determined by the conversion of chloramphenicol to its acetylated forms.
Dotma (Lipofectin, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dotma (lipofectin/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
dotma (lipofectin - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Thermo Fisher dotma/dope (lipofectin
Inhibition of HIV-1 infectivity by a MAPK antisense oligonucleotide (AS) or scrambled control oligonucleotide (SC). (A) Depletion of p44/42 MAPK expression by AS. HeLa cells were treated with AS or SC at the indicated concentrations. HeLa cells were grown to 80% confluence in Dulbecco’s minimal essential medium (DMEM) containing 10% FCS in 35-mm-diameter six-well plates, and washed twice with serum-free DMEM. Appropriate concentrations of oligonucleotides in 125 μl of serum-free DMEM were preincubated at room temperature for 15 min with 125 μl of serum-free DMEM containing 40 μg of <t>DOTMA</t> <t>(Lipofectin)</t> (Gibco-BRL) per ml. This solution was then mixed with an additional 250 μl of serum-free DMEM. Cells were incubated with the mixture for 6 h at 37°C in the presence of 5% CO2. Subsequently, the medium containing DOTMA was removed and the incubation was continued for 48 h in fresh medium containing 10% FCS. After 48 h incubation, MAPK expression was determined by immunoblotting of equivalent amounts of total protein with anti-MAPK (anti-ERK1 [p44] and anti-ERK2 [p42]). (B) HeLa cells were transfected with 3 μg of pHXB2 containing HIV-1 proviral DNA following depletion of MAPK by treatment with MAPK antisense oligonucleotide as described for panel A. Virus production was determined by quantitation of RT activity in the supernatants of the transfected HeLa cell cultures at 48 h after transfection. Virus infectivity was determined by infection of CEM cells and quantitation of RT activity in the supernatants of the newly infected cells on day 7 after infection. (C) Treatment with AS does not inhibit expression of an HIV-1 LTR CAT reporter plasmid transactivated by coexpression of HIV-1 Tat. HeLa cells were treated with the oligonucleotides at 0.2 μM and cotransfected with 0.5 μg of pUIIIRCAT and 0 or 0.5 μg of the HIV-1 Tat expressor plasmid pSVLtat by the same method as described for panels A and B. Shown is CAT activity in the transfected cell lysate at 48 h posttransfection, as determined by the conversion of chloramphenicol to its acetylated forms.
Dotma/Dope (Lipofectin, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dotma/dope (lipofectin/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
dotma/dope (lipofectin - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

86
Thermo Fisher dotma dope
Inhibition of HIV-1 infectivity by a MAPK antisense oligonucleotide (AS) or scrambled control oligonucleotide (SC). (A) Depletion of p44/42 MAPK expression by AS. HeLa cells were treated with AS or SC at the indicated concentrations. HeLa cells were grown to 80% confluence in Dulbecco’s minimal essential medium (DMEM) containing 10% FCS in 35-mm-diameter six-well plates, and washed twice with serum-free DMEM. Appropriate concentrations of oligonucleotides in 125 μl of serum-free DMEM were preincubated at room temperature for 15 min with 125 μl of serum-free DMEM containing 40 μg of <t>DOTMA</t> <t>(Lipofectin)</t> (Gibco-BRL) per ml. This solution was then mixed with an additional 250 μl of serum-free DMEM. Cells were incubated with the mixture for 6 h at 37°C in the presence of 5% CO2. Subsequently, the medium containing DOTMA was removed and the incubation was continued for 48 h in fresh medium containing 10% FCS. After 48 h incubation, MAPK expression was determined by immunoblotting of equivalent amounts of total protein with anti-MAPK (anti-ERK1 [p44] and anti-ERK2 [p42]). (B) HeLa cells were transfected with 3 μg of pHXB2 containing HIV-1 proviral DNA following depletion of MAPK by treatment with MAPK antisense oligonucleotide as described for panel A. Virus production was determined by quantitation of RT activity in the supernatants of the transfected HeLa cell cultures at 48 h after transfection. Virus infectivity was determined by infection of CEM cells and quantitation of RT activity in the supernatants of the newly infected cells on day 7 after infection. (C) Treatment with AS does not inhibit expression of an HIV-1 LTR CAT reporter plasmid transactivated by coexpression of HIV-1 Tat. HeLa cells were treated with the oligonucleotides at 0.2 μM and cotransfected with 0.5 μg of pUIIIRCAT and 0 or 0.5 μg of the HIV-1 Tat expressor plasmid pSVLtat by the same method as described for panels A and B. Shown is CAT activity in the transfected cell lysate at 48 h posttransfection, as determined by the conversion of chloramphenicol to its acetylated forms.
Dotma Dope, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dotma dope/product/Thermo Fisher
Average 86 stars, based on 1 article reviews
dotma dope - by Bioz Stars, 2026-04
86/100 stars
  Buy from Supplier

90
Thermo Fisher lipofectamine
Inhibition of HIV-1 infectivity by a MAPK antisense oligonucleotide (AS) or scrambled control oligonucleotide (SC). (A) Depletion of p44/42 MAPK expression by AS. HeLa cells were treated with AS or SC at the indicated concentrations. HeLa cells were grown to 80% confluence in Dulbecco’s minimal essential medium (DMEM) containing 10% FCS in 35-mm-diameter six-well plates, and washed twice with serum-free DMEM. Appropriate concentrations of oligonucleotides in 125 μl of serum-free DMEM were preincubated at room temperature for 15 min with 125 μl of serum-free DMEM containing 40 μg of <t>DOTMA</t> <t>(Lipofectin)</t> (Gibco-BRL) per ml. This solution was then mixed with an additional 250 μl of serum-free DMEM. Cells were incubated with the mixture for 6 h at 37°C in the presence of 5% CO2. Subsequently, the medium containing DOTMA was removed and the incubation was continued for 48 h in fresh medium containing 10% FCS. After 48 h incubation, MAPK expression was determined by immunoblotting of equivalent amounts of total protein with anti-MAPK (anti-ERK1 [p44] and anti-ERK2 [p42]). (B) HeLa cells were transfected with 3 μg of pHXB2 containing HIV-1 proviral DNA following depletion of MAPK by treatment with MAPK antisense oligonucleotide as described for panel A. Virus production was determined by quantitation of RT activity in the supernatants of the transfected HeLa cell cultures at 48 h after transfection. Virus infectivity was determined by infection of CEM cells and quantitation of RT activity in the supernatants of the newly infected cells on day 7 after infection. (C) Treatment with AS does not inhibit expression of an HIV-1 LTR CAT reporter plasmid transactivated by coexpression of HIV-1 Tat. HeLa cells were treated with the oligonucleotides at 0.2 μM and cotransfected with 0.5 μg of pUIIIRCAT and 0 or 0.5 μg of the HIV-1 Tat expressor plasmid pSVLtat by the same method as described for panels A and B. Shown is CAT activity in the transfected cell lysate at 48 h posttransfection, as determined by the conversion of chloramphenicol to its acetylated forms.
Lipofectamine, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lipofectamine/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
lipofectamine - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

86
Thermo Fisher dotma pe
Inhibition of HIV-1 infectivity by a MAPK antisense oligonucleotide (AS) or scrambled control oligonucleotide (SC). (A) Depletion of p44/42 MAPK expression by AS. HeLa cells were treated with AS or SC at the indicated concentrations. HeLa cells were grown to 80% confluence in Dulbecco’s minimal essential medium (DMEM) containing 10% FCS in 35-mm-diameter six-well plates, and washed twice with serum-free DMEM. Appropriate concentrations of oligonucleotides in 125 μl of serum-free DMEM were preincubated at room temperature for 15 min with 125 μl of serum-free DMEM containing 40 μg of <t>DOTMA</t> <t>(Lipofectin)</t> (Gibco-BRL) per ml. This solution was then mixed with an additional 250 μl of serum-free DMEM. Cells were incubated with the mixture for 6 h at 37°C in the presence of 5% CO2. Subsequently, the medium containing DOTMA was removed and the incubation was continued for 48 h in fresh medium containing 10% FCS. After 48 h incubation, MAPK expression was determined by immunoblotting of equivalent amounts of total protein with anti-MAPK (anti-ERK1 [p44] and anti-ERK2 [p42]). (B) HeLa cells were transfected with 3 μg of pHXB2 containing HIV-1 proviral DNA following depletion of MAPK by treatment with MAPK antisense oligonucleotide as described for panel A. Virus production was determined by quantitation of RT activity in the supernatants of the transfected HeLa cell cultures at 48 h after transfection. Virus infectivity was determined by infection of CEM cells and quantitation of RT activity in the supernatants of the newly infected cells on day 7 after infection. (C) Treatment with AS does not inhibit expression of an HIV-1 LTR CAT reporter plasmid transactivated by coexpression of HIV-1 Tat. HeLa cells were treated with the oligonucleotides at 0.2 μM and cotransfected with 0.5 μg of pUIIIRCAT and 0 or 0.5 μg of the HIV-1 Tat expressor plasmid pSVLtat by the same method as described for panels A and B. Shown is CAT activity in the transfected cell lysate at 48 h posttransfection, as determined by the conversion of chloramphenicol to its acetylated forms.
Dotma Pe, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dotma pe/product/Thermo Fisher
Average 86 stars, based on 1 article reviews
dotma pe - by Bioz Stars, 2026-04
86/100 stars
  Buy from Supplier

90
Thermo Fisher lipofectin registered™
Inhibition of HIV-1 infectivity by a MAPK antisense oligonucleotide (AS) or scrambled control oligonucleotide (SC). (A) Depletion of p44/42 MAPK expression by AS. HeLa cells were treated with AS or SC at the indicated concentrations. HeLa cells were grown to 80% confluence in Dulbecco’s minimal essential medium (DMEM) containing 10% FCS in 35-mm-diameter six-well plates, and washed twice with serum-free DMEM. Appropriate concentrations of oligonucleotides in 125 μl of serum-free DMEM were preincubated at room temperature for 15 min with 125 μl of serum-free DMEM containing 40 μg of <t>DOTMA</t> <t>(Lipofectin)</t> (Gibco-BRL) per ml. This solution was then mixed with an additional 250 μl of serum-free DMEM. Cells were incubated with the mixture for 6 h at 37°C in the presence of 5% CO2. Subsequently, the medium containing DOTMA was removed and the incubation was continued for 48 h in fresh medium containing 10% FCS. After 48 h incubation, MAPK expression was determined by immunoblotting of equivalent amounts of total protein with anti-MAPK (anti-ERK1 [p44] and anti-ERK2 [p42]). (B) HeLa cells were transfected with 3 μg of pHXB2 containing HIV-1 proviral DNA following depletion of MAPK by treatment with MAPK antisense oligonucleotide as described for panel A. Virus production was determined by quantitation of RT activity in the supernatants of the transfected HeLa cell cultures at 48 h after transfection. Virus infectivity was determined by infection of CEM cells and quantitation of RT activity in the supernatants of the newly infected cells on day 7 after infection. (C) Treatment with AS does not inhibit expression of an HIV-1 LTR CAT reporter plasmid transactivated by coexpression of HIV-1 Tat. HeLa cells were treated with the oligonucleotides at 0.2 μM and cotransfected with 0.5 μg of pUIIIRCAT and 0 or 0.5 μg of the HIV-1 Tat expressor plasmid pSVLtat by the same method as described for panels A and B. Shown is CAT activity in the transfected cell lysate at 48 h posttransfection, as determined by the conversion of chloramphenicol to its acetylated forms.
Lipofectin Registered™, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lipofectin registered™/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
lipofectin registered™ - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Thermo Fisher cationic lipid dotma/dope (lipofectin
Inhibition of HIV-1 infectivity by a MAPK antisense oligonucleotide (AS) or scrambled control oligonucleotide (SC). (A) Depletion of p44/42 MAPK expression by AS. HeLa cells were treated with AS or SC at the indicated concentrations. HeLa cells were grown to 80% confluence in Dulbecco’s minimal essential medium (DMEM) containing 10% FCS in 35-mm-diameter six-well plates, and washed twice with serum-free DMEM. Appropriate concentrations of oligonucleotides in 125 μl of serum-free DMEM were preincubated at room temperature for 15 min with 125 μl of serum-free DMEM containing 40 μg of <t>DOTMA</t> <t>(Lipofectin)</t> (Gibco-BRL) per ml. This solution was then mixed with an additional 250 μl of serum-free DMEM. Cells were incubated with the mixture for 6 h at 37°C in the presence of 5% CO2. Subsequently, the medium containing DOTMA was removed and the incubation was continued for 48 h in fresh medium containing 10% FCS. After 48 h incubation, MAPK expression was determined by immunoblotting of equivalent amounts of total protein with anti-MAPK (anti-ERK1 [p44] and anti-ERK2 [p42]). (B) HeLa cells were transfected with 3 μg of pHXB2 containing HIV-1 proviral DNA following depletion of MAPK by treatment with MAPK antisense oligonucleotide as described for panel A. Virus production was determined by quantitation of RT activity in the supernatants of the transfected HeLa cell cultures at 48 h after transfection. Virus infectivity was determined by infection of CEM cells and quantitation of RT activity in the supernatants of the newly infected cells on day 7 after infection. (C) Treatment with AS does not inhibit expression of an HIV-1 LTR CAT reporter plasmid transactivated by coexpression of HIV-1 Tat. HeLa cells were treated with the oligonucleotides at 0.2 μM and cotransfected with 0.5 μg of pUIIIRCAT and 0 or 0.5 μg of the HIV-1 Tat expressor plasmid pSVLtat by the same method as described for panels A and B. Shown is CAT activity in the transfected cell lysate at 48 h posttransfection, as determined by the conversion of chloramphenicol to its acetylated forms.
Cationic Lipid Dotma/Dope (Lipofectin, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cationic lipid dotma/dope (lipofectin/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
cationic lipid dotma/dope (lipofectin - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Inhibition of HIV-1 infectivity by a MAPK antisense oligonucleotide (AS) or scrambled control oligonucleotide (SC). (A) Depletion of p44/42 MAPK expression by AS. HeLa cells were treated with AS or SC at the indicated concentrations. HeLa cells were grown to 80% confluence in Dulbecco’s minimal essential medium (DMEM) containing 10% FCS in 35-mm-diameter six-well plates, and washed twice with serum-free DMEM. Appropriate concentrations of oligonucleotides in 125 μl of serum-free DMEM were preincubated at room temperature for 15 min with 125 μl of serum-free DMEM containing 40 μg of DOTMA (Lipofectin) (Gibco-BRL) per ml. This solution was then mixed with an additional 250 μl of serum-free DMEM. Cells were incubated with the mixture for 6 h at 37°C in the presence of 5% CO2. Subsequently, the medium containing DOTMA was removed and the incubation was continued for 48 h in fresh medium containing 10% FCS. After 48 h incubation, MAPK expression was determined by immunoblotting of equivalent amounts of total protein with anti-MAPK (anti-ERK1 [p44] and anti-ERK2 [p42]). (B) HeLa cells were transfected with 3 μg of pHXB2 containing HIV-1 proviral DNA following depletion of MAPK by treatment with MAPK antisense oligonucleotide as described for panel A. Virus production was determined by quantitation of RT activity in the supernatants of the transfected HeLa cell cultures at 48 h after transfection. Virus infectivity was determined by infection of CEM cells and quantitation of RT activity in the supernatants of the newly infected cells on day 7 after infection. (C) Treatment with AS does not inhibit expression of an HIV-1 LTR CAT reporter plasmid transactivated by coexpression of HIV-1 Tat. HeLa cells were treated with the oligonucleotides at 0.2 μM and cotransfected with 0.5 μg of pUIIIRCAT and 0 or 0.5 μg of the HIV-1 Tat expressor plasmid pSVLtat by the same method as described for panels A and B. Shown is CAT activity in the transfected cell lysate at 48 h posttransfection, as determined by the conversion of chloramphenicol to its acetylated forms.

Journal:

Article Title: Regulation of Human Immunodeficiency Virus Type 1 Infectivity by the ERK Mitogen-Activated Protein Kinase Signaling Pathway

doi:

Figure Lengend Snippet: Inhibition of HIV-1 infectivity by a MAPK antisense oligonucleotide (AS) or scrambled control oligonucleotide (SC). (A) Depletion of p44/42 MAPK expression by AS. HeLa cells were treated with AS or SC at the indicated concentrations. HeLa cells were grown to 80% confluence in Dulbecco’s minimal essential medium (DMEM) containing 10% FCS in 35-mm-diameter six-well plates, and washed twice with serum-free DMEM. Appropriate concentrations of oligonucleotides in 125 μl of serum-free DMEM were preincubated at room temperature for 15 min with 125 μl of serum-free DMEM containing 40 μg of DOTMA (Lipofectin) (Gibco-BRL) per ml. This solution was then mixed with an additional 250 μl of serum-free DMEM. Cells were incubated with the mixture for 6 h at 37°C in the presence of 5% CO2. Subsequently, the medium containing DOTMA was removed and the incubation was continued for 48 h in fresh medium containing 10% FCS. After 48 h incubation, MAPK expression was determined by immunoblotting of equivalent amounts of total protein with anti-MAPK (anti-ERK1 [p44] and anti-ERK2 [p42]). (B) HeLa cells were transfected with 3 μg of pHXB2 containing HIV-1 proviral DNA following depletion of MAPK by treatment with MAPK antisense oligonucleotide as described for panel A. Virus production was determined by quantitation of RT activity in the supernatants of the transfected HeLa cell cultures at 48 h after transfection. Virus infectivity was determined by infection of CEM cells and quantitation of RT activity in the supernatants of the newly infected cells on day 7 after infection. (C) Treatment with AS does not inhibit expression of an HIV-1 LTR CAT reporter plasmid transactivated by coexpression of HIV-1 Tat. HeLa cells were treated with the oligonucleotides at 0.2 μM and cotransfected with 0.5 μg of pUIIIRCAT and 0 or 0.5 μg of the HIV-1 Tat expressor plasmid pSVLtat by the same method as described for panels A and B. Shown is CAT activity in the transfected cell lysate at 48 h posttransfection, as determined by the conversion of chloramphenicol to its acetylated forms.

Article Snippet: Appropriate concentrations of oligonucleotides in 125 μl of serum-free DMEM were preincubated at room temperature for 15 min with 125 μl of serum-free DMEM containing 40 μg of DOTMA (Lipofectin) (Gibco-BRL) per ml.

Techniques: Inhibition, Infection, Expressing, Incubation, Western Blot, Transfection, Quantitation Assay, Activity Assay, Plasmid Preparation